RenovoRx to Detail Progress on Targeted Cancer Therapies, TIGeR-PaC Trial
Event summary
- RenovoRx will host a conference call on March 30, 2026, at 4:30 p.m. ET to discuss Q4 and full-year 2025 financial results and business highlights.
- Management will discuss adoption of RenovoCath among U.S. cancer centers and progress on the Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer.
- Enrollment in the TIGeR-PaC trial is expected to complete in the first half of 2026, with final data anticipated in 2027.
- RenovoRx generated approximately $900,000 in revenue from RenovoCath sales during the first nine months of 2025.
The big picture
RenovoRx's strategy of combining targeted drug delivery with clinical trials represents a capital-efficient approach to oncology drug development, but hinges on demonstrating clinical efficacy and achieving commercial adoption of its RenovoCath device. The company’s reliance on investigator-initiated trials and registry studies to generate data highlights the challenges of securing broader regulatory approval and market acceptance for its TAMP platform.
What we're watching
- Clinical Execution
- The success of the TIGeR-PaC trial hinges on timely enrollment and positive data readouts, which will significantly impact RenovoRx’s valuation.
- Commercial Traction
- Whether RenovoRx can sustain the initial momentum in RenovoCath adoption and expand beyond early adopters will be critical for revenue growth.
- Regulatory Pathway
- The FDA's evaluation of the IAG combination product and potential for accelerated approval will dictate the timeline for commercialization and market access.
Related topics